Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | BCDIN3D | Q7Z5W3 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22805485 | 1.00 | PDE2A (0.72) | PDE2AGAABCDIN3DKMT2AMEN1 | |
| SCHEMBL22806016 | 0.85 | GAA (0.80) | PDE2AGAABCDIN3DKMT2AMEN1 | |
| SCHEMBL29582070 | 0.85 | GAA (0.80) | PDE2AGAABCDIN3DKMT2AMEN1 | |
| SCHEMBL29487090 | 0.85 | BCDIN3D (0.67) | BCDIN3DHTR2C | |
| SCHEMBL13087256 | 0.84 | GAA (0.78) | PDE2AGAAKMT2AMEN1HTR2C | |
| SCHEMBL20240162 | 0.84 | PDE2A (1.00) | PDE2AGAAKMT2A | |
| SCHEMBL22806464 | 0.82 | BCDIN3D (0.63) | PDE2AGAABCDIN3DKMT2AMEN1 | |
| SCHEMBL29582062 | 0.82 | BCDIN3D (0.63) | PDE2AGAABCDIN3DKMT2AMEN1 | |
| SCHEMBL20240174 | 0.82 | PDE2A (1.00) | PDE2ABCDIN3D | |
| SCHEMBL22805568 | 0.81 | BCDIN3D (0.60) | BCDIN3DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | STORM THERAPEUTICS LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114286711-A | Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity | 风暴治疗有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | BCDIN3D, CDK3, CCNI | PDE2A 3676/4885GAA 673/4885BCDIN3D 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.